Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmathen generic brinzolamide + brimonidine versus Simbrinza in open-angle glaucoma or ocular hypertension
2020-000079-18Phase 3Terminated
- Sponsor
- Pharmathen
- Start
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of brinzolamide and brimonidine in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Pharmathen. Started Feb 2020; status: terminated.
02
Drugs
brinzolamidebrimonidine
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2020-000079-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000079-18.